Our results are well in agreement with other experimental studies showing that AVP is involved in the pathophysiology of brain damage, Bhandari et al. 31 effectively attenuated the brain edema secondary to intracerebral hemorrhage (ICH) in animals treated with Tolvaptan, an AVP-V2 receptor antagonist; they also showed a decrease in BBB permeability to Evans blue tracer in the Tolvaptan-treated ICH animals as compared to the ICH group31. The gene discussed is AVP; the disease is intracerebral hemorrhage.